Systemic amyloidosis is a rare, progressive disease caused by the deposition of abnormal protein fibers known as amyloid in various tissues and organs of the body, including the heart, kidneys, liver, spleen, and nervous system. The growing morbidity and mortality associated with amyloidosis disorders have propelled research initiatives focused on developing novel therapeutic agents and treatment strategies. Currently, the systemic amyloidosis therapeutic market offers symptom management and organ transplantation as conventional treatment lines.

The Global Systemic Amyloidosis Therapeutic Market is estimated to be valued at USD 6.19 Bn in 2024 and is expected to reach USD 10.99 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.9% from 2024 to 2031.

Key players operating in the systemic amyloidosis therapeutic market are Pfizer Inc., Baxter, Alnylam Pharmaceuticals, Prothena Corporation plc., GlaxoSmithKline plc., and others. These players are focusing on new product launches and inorganic growth strategies such as acquisitions and collaborations to strengthen their market position.



The rising research spending to develop disease-modifying drugs and novel therapeutic targets, along with the increasing partnerships between drug makers and research institutes represent major growth opportunities in the Systemic Amyloidosis Therapeutic Market.



Globally, North America dominates the systemic amyloidosis therapeutic market and is estimated to continue its dominance over the forecast period owing to the high prevalence of amyloidosis, availability of advanced treatment options, and presence of key players. However, Asia Pacific is expected to exhibit the highest growth rate over the coming years due to improving healthcare facilities, increasing healthcare expenditure, and growing awareness regarding amyloidosis.

Market Drivers

The rapidly increasing prevalence of amyloidosis diseases worldwide due to the aging population and the growing incidence of chronic disorders are majorly driving the growth of the systemic amyloidosis therapeutic market. According to the Yale School of Medicine, the prevalence of amyloidosis has increased from 5-10 per million in the early 1990s to approximately 20-30 per million currently. Additionally, rising research and development investments by key players to develop novel disease-modifying therapies are further expected to propel the market growth over the forecast period.

PEST Analysis

Political: The regulatory policies of the healthcare sector will determine the growth avenues for companies operating in this market.



Economic: Factors such as rise in healthcare spending and increasing investment in R&D will impact the overall sales numbers of systemic amyloidosis therapeutics.



Social: Increasing public awareness about the disease condition and available treatment options will drive more people to adopt therapy.



Technological: Advancements in diagnostic techniques and development of novel drug molecules will help improve treatment outcomes and clinical efficacy. Investments made by players for developing customized therapies will also boost their positions.



Geographical regions concentrating market value

North America currently accounts for the largest share of the systemic amyloidosis therapeutics market owing to established healthcare infrastructure and presence of major pharma companies in the region. Europe holds the second largest regional market due to growing prevalence of the disease and availability of advanced treatment facilities.



Fastest growing regional market

The Asian market is projected to witness the highest growth during the forecast period. This can be attributed to increasing healthcare spending, rising disposable incomes, growing awareness about the disease, and improving access to diagnosis and care. Initiatives undertaken by governments in various Asian countries to strengthen their healthcare systems are also aiding market expansion.

Get this Report in Japanese Language: 全身性アミロイドーシス治療市場

Get this Report in Korean Language: 전신성 아밀로이드증 치료 시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)